Want to see EVMN full AI Analyst Report?

Evommune, Inc. (EVMN) Stock Forecast & Price Target

135 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EVMN Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Evommune,

Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EVMN Stock 12 Month Forecast

Average Price Target

$34.83

▲(147.40% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Evommune, Inc. in the last 3 months. The average price target is $34.83 with a high forecast of $54.00 and a low forecast of $22.00. The average price target represents a 147.40% change from the last price of $14.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","55":"$55","21.25":"$21.3","32.5":"$32.5","43.75":"$43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.833333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,21.25,32.5,43.75,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.25,14.538461538461538,17.826923076923077,21.115384615384613,24.403846153846153,27.692307692307693,30.98076923076923,34.26923076923077,37.55769230769231,40.84615384615385,44.13461538461539,47.42307692307692,50.71153846153846,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.25,13.064102564102564,14.878205128205128,16.692307692307693,18.506410256410255,20.32051282051282,22.134615384615387,23.94871794871795,25.762820512820515,27.57692307692308,29.391025641025642,31.205128205128208,33.019230769230774,{"y":34.833333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.25,12.076923076923077,12.903846153846153,13.73076923076923,14.557692307692307,15.384615384615383,16.21153846153846,17.03846153846154,17.865384615384613,18.692307692307693,19.519230769230766,20.346153846153847,21.173076923076923,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.23,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.23,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.23,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.23,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.17,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.82,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.25,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$54.00

Average Price Target$34.83

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-Gartner

Evercore ISI

$22

Buy

56.25%

Upside

Reiterated

08/10/26

Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)

Judah Frommer

Morgan Stanley

$26

Buy

84.66%

Upside

Assigned

08/10/26

Analysts Conflicted on These NA Names: TripAdvisor (NASDAQ: TRIP), Evommune, Inc. (NYSE: EVMN) and StandardAero, Inc. (NYSE: SARO)

Mitchell Kapoor

H.C. Wainwright

―

Hold

―

Reiterated

08/07/26

Analysts Conflicted on These NA Names: Bob's Discount Furniture, Inc. (NYSE: BOBS), Evommune, Inc. (NYSE: EVMN) and Once Upon a Farm, PBC (NYSE: OFRM)

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/07/26

Analysts Conflicted on These NA Names: Fiserv (NASDAQ: FISV), Evommune, Inc. (NYSE: EVMN) and Waystar Holding Corp. (NASDAQ: WAY)

Brian Abrahams

RBC Capital

$30→$29

Buy

105.97%

Upside

Reiterated

08/06/26

RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN)

Kaveri Pohlman

Clear Street

$28

Buy

98.86%

Upside

Reiterated

07/16/26

Clear Street sees attractive point into Evommune after selloffClear Street sees attractive point into Evommune after selloff

Alex Thompson CFA

Stifel Nicolaus

$54

Buy

283.52%

Upside

Reiterated

07/06/26

Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)

Kostas Biliouris

Oppenheimer

$50

Buy

255.11%

Upside

Reiterated

05/15/26

Oppenheimer Sticks to Its Buy Rating for Evommune, Inc. (EVMN)

Thomas Smith

Leerink Partners

$52

Buy

269.32%

Upside

Reiterated

03/06/26

Evommune, Inc. (EVMN) Receives a Rating Update from a Top Analyst

Martin Auster

Raymond James

$40

Buy

184.09%

Upside

Reiterated

01/26/26

Evommune, Inc. (EVMN) Receives a Buy from Raymond James

Andreas Argyrides

Chardan Capital

$42

Buy

198.30%

Upside

Initiated

01/23/26

Evommune initiated with an Outperform at OppenheimerEvommune initiated with an Outperform at Oppenheimer

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Initiated

12/01/25

Evommune initiated with an Overweight at Cantor FitzgeraldEvommune initiated with an Overweight at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-Gartner

Evercore ISI

$22

Buy

56.25%

Upside

Reiterated

08/10/26

Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)

Judah Frommer

Morgan Stanley

$26

Buy

84.66%

Upside

Assigned

08/10/26

Analysts Conflicted on These NA Names: TripAdvisor (NASDAQ: TRIP), Evommune, Inc. (NYSE: EVMN) and StandardAero, Inc. (NYSE: SARO)

Mitchell Kapoor

H.C. Wainwright

―

Hold

―

Reiterated

08/07/26

Analysts Conflicted on These NA Names: Bob's Discount Furniture, Inc. (NYSE: BOBS), Evommune, Inc. (NYSE: EVMN) and Once Upon a Farm, PBC (NYSE: OFRM)

Matt Phipps

William Blair

―

Hold

―

Reiterated

08/07/26

Analysts Conflicted on These NA Names: Fiserv (NASDAQ: FISV), Evommune, Inc. (NYSE: EVMN) and Waystar Holding Corp. (NASDAQ: WAY)

Brian Abrahams

RBC Capital

$30→$29

Buy

105.97%

Upside

Reiterated

08/06/26

RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN)

Kaveri Pohlman

Clear Street

$28

Buy

98.86%

Upside

Reiterated

07/16/26

Clear Street sees attractive point into Evommune after selloffClear Street sees attractive point into Evommune after selloff

Alex Thompson CFA

Stifel Nicolaus

$54

Buy

283.52%

Upside

Reiterated

07/06/26

Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)

Kostas Biliouris

Oppenheimer

$50

Buy

255.11%

Upside

Reiterated

05/15/26

Oppenheimer Sticks to Its Buy Rating for Evommune, Inc. (EVMN)

Thomas Smith

Leerink Partners

$52

Buy

269.32%

Upside

Reiterated

03/06/26

Evommune, Inc. (EVMN) Receives a Rating Update from a Top Analyst

Martin Auster

Raymond James

$40

Buy

184.09%

Upside

Reiterated

01/26/26

Evommune, Inc. (EVMN) Receives a Buy from Raymond James

Andreas Argyrides

Chardan Capital

$42

Buy

198.30%

Upside

Initiated

01/23/26

Evommune initiated with an Outperform at OppenheimerEvommune initiated with an Outperform at Oppenheimer

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Initiated

12/01/25

Evommune initiated with an Overweight at Cantor FitzgeraldEvommune initiated with an Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Evommune, Inc.

3 Months

Kaveri PohlmanClear Street

Success Rate

1/3 ratings generated profit

Average Return

-1.20%

Copying Kaveri Pohlman's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -1.20% per trade.

1 Year

Kaveri PohlmanClear Street

Success Rate

1/3 ratings generated profit

Average Return

-9.97%

Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -9.97% per trade.

2 Years

Kaveri PohlmanClear Street

Success Rate

1/3 ratings generated profit

Average Return

-9.97%

Copying Kaveri Pohlman's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -9.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EVMN Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EVMN has received 10 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. EVMN average Analyst price target in the past 3 months is 34.83.

Each month's total comprises the sum of three months' worth of ratings.

EVMN Financial Forecast

EVMN Earnings Forecast

Next quarter’s earnings estimate for EVMN is -$0.83 with a range of -$1.01 to -$0.64. The previous quarter’s EPS was -$0.89. EVMN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 49.79% of the time in the same period. In the last calendar year EVMN has Performed in-line its overall industry.

EVMN Sales Forecast

Next quarter’s sales forecast for EVMN is $500.00K with a range of $0.00 to $3.00M. The previous quarter’s sales results were $0.00. EVMN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 62.80% of the time in the same period. In the last calendar year EVMN has Performed in-line its overall industry.

EVMN Stock Forecast FAQ

What is EVMN’s average 12-month price target, according to analysts?

Based on analyst ratings, Evommune, Inc.’s 12-month average price target is 34.83.

What is EVMN’s upside potential, based on the analysts’ average price target?

Evommune, Inc. has 147.40% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EVMN a Buy, Sell or Hold?

Evommune, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Evommune, Inc.’s price target?

The average price target for Evommune, Inc. is 34.83. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $54.00 ,the lowest forecast is $22.00. The average price target represents 147.40% Increase from the current price of $14.08.

What do analysts say about Evommune, Inc.?

Evommune, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of EVMN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Evommune, Inc. (EVMN) Stock Forecast & Price Target

EVMN Analyst Ratings

EVMN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Evommune, Inc.

EVMN Analyst Recommendation Trends

EVMN Financial Forecast

EVMN Earnings Forecast

EVMN Sales Forecast

EVMN Stock Forecast FAQ

Detailed List of Analyst Forecasts